Two peptide derivatives of glucosamine that are more effective in controlling joint inflammation and in stimulating the formation of new cartilage tissue
The past several decades has seen a substantial increase in the incidence of pain and morbidity associated with idiopathic osteoarthritis of the knee and hip joints. Analgesics and non-steroidal anti-inflammatory drugs are currently extensively used as non-surgical treatment options. They act, however, only as palliative symptomatic treatments, and they are not disease-modifying, do not offer a cure, and have recently been associated with an increased risk for adverse events (1).
Cartilago’s proprietary technology provides a novel approach that addresses the underlying pathology by acting as a disease-modifying chondroprotective. As such, it would enter the market as one of the first disease-modifying osteoarthritis drugs, and offer not just symptomatic relief, but also inhibit the typical natural progression of the disease.
Cartilago’s technology additionally has applications in numerous other fields, including oncology and skincare, and is currently being explored and developed for use in these areas. Notably, certain chronic inflammatory pathways within Cartilago’s realm of R&D and knowhow have been shown to be associated with carcinogenesis, and the specific signal transduction pathway involved has been deciphered. This pathway will be exploited as a molecular target for drug discovery.
Cartilago is an academic spin-off that has developed a groundbreaking technology for combatting joint inflammation and stimulating the formation of new cartilage tissue. Glucosamine is the basic molecule for the synthesis of macromolecules present in cartilage, tendons, and ligaments. In addition to stimulating cartilage production, glucosamine also reduces joint pain and inflammation (1). Cartilago’s technology is premised on two peptide derivatives of glucosamine, both far more potent than the parent molecule, that have shown extraordinary efficacy in cartilage reconstruction and collagen repair.
Evidence indicates that these peptides may be developed and exploited in the fields of osteoarthritis, anti-aging and oncology.
Osteoarthritis: Cartilago’s peptides display significant more potency and efficacy in stimulating tissue repair, generation of extracellular matrix, and the endogenous production of hyaluronic acid and a specific type of collagen than glucosamine in comprehensive testing.
Anti-aging: Cartilago’s skin care products were developed to address an unmet market need for a natural and physiological solution for the healthy maintenance of the skin, fostering rejuvenation through core transduction pathways and avoiding the typical local injection discomfort common to most current skincare solutions. Currently available anti-aging solutions involving hyaluronic acid comprise dermal fillers. Such dermal fillers are absorbable and therefore have transient effects. In comparison, Cartilago’s skincare solution is administered topically, allowing for a long lasting effect and the stimulation of endogenous hyaluronic acid production.
Oncology: Cartilago has elucidated the specific signal transduction pathways that are the targets of its proprietary products. Its discovery efforts have led to the hypothesis that one of its peptide derivatives has anti-metastatic activity. Indeed, prelimenary tests demonstrate that the pleiotropic effects of the molecule act to significantly suppress human osteosarcoma cells’ ability to metastasize. It is currently being further evaluated for development in this area.
Cartilago’s CSO is the author of more than 130 publications on international peer-reviewed journals and is a nationally recognized expert in his field.
The core of the technology is centered around a peptide derived from the natural amino monosaccharide glucosamine, which Cartilago has proven to be more effective in vitro than the parent molecule in stimulating the generation of extracellular matrix, endogenous hyaluronic acid production and a specific type of collagen. Preclinical research has demonstrated that the pipeline product has collagen repair properties and stimulates endogenous hyaluronic acid production.
Moreover, cutting edge 3D cell culture techniques have been employed to reproduce the three-dimensional physiologic structure of human dermal tissues, and this model used to affirm the properties of this peptide.
The new molecule is being developed for use in joint disease, such as osteoarthritis or diseases characterized by lack of cartilage; in cosmetics to treat signs of aging and skin imperfections; and in Sports Medicine for the treatment of traumas or pathologies affecting the joints where it is necessary to stimulate the production of new cartilage.
Clinical studies have demonstrated that the molecule has extraordinary efficacy in stimulating the production of new cartilage tissue and new extracellular matrix, one of the components of the dermis.
Moreover, the mechanism of action of another one of Cartilago’s peptide derivatives indicates it can suppress metastasis in osteosarcoma, and preclinical tests conducted thus far support this hypothesis.
The first molecule, then:
- Stimulates the endogenous production of cartilage and new tissue;
- Ease pathological joint states characterized by chronic pain;
- Acts to repair and regenerate the extracellular matrix and aged tissues;
- Stimulates tissue regeneration without the need for invasive external interventions;
- Acts not transiently but long term.
The second molecule:
- Inhibits the metastasis of human osteosarcoma cells.
Cartilago is creating a line of products that exploits the therapeutic properties of its potent proprietary molecules.
“The Regen Product Line” targets four areas of therapy:
Beauty and Anti-aging
- Regen Beauty Cream for Face
- Regen Beauty Fluid serum for Body
- Intra-articular Infiltrations Regular IA
- Regen Repair Wound Care Gel Nutraceutical: Food supplement (tablets) Regen Nutro